Current Report · Items 5.02, 7.01, 9.01 · 8-K

Insulet Corporation

PODDNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure

Filed Jun 25, 2026Accepted Jun 25, 2026, 7:06 AM EDTCIK 1145197Accession 0001145197-26-000148

Company context

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com.

Current securities

PODDNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 24, 2026, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky will stand for election by stockholders at the Company’s 2027 Annual Meeting of Stockholders. Mr. Mazelsky has been the Executive Chair of the board of directors of IDEXX Laboratories, Inc. since May 2026. He also served at IDEXX as President and Chief Executive Officer from October 2019 to May 2026, as Interim President and Chief Executive Officer from June 2019 to October 2019, and as Executive Vice President responsible for IDEXX’s North American Companion Animal Group Commercial Organization and key elements of their innovation portfolio from August 2012 to June 2019. From 2010 to 2012, he served as Senior Vice President and General Manager, Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips), where he also held roles of increasing responsibility from 2001 to 2010. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips, and General Manager of Agilent’s Medical Consumables Business Unit from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. He is currently a member of the board of directors of Dentsply Sirona Inc. Mr. Mazelsky has an M.B.A. from the University of Chicago Booth School of Business and a B.A. in Mathematics from the University of Rochester. There are no arrangements or understandings between Mr. Mazelsky and any other persons pursuant to which he was selected as a director. There are no transactions involving Mr. Mazelsky required to be disclosed under Item 404(a) of Regulation S-K. As a non-employee director of the Company, Mr. Mazelsky will receive an initial grant of restricted stock units with a grant date fair value of $216,548, which represents a pro-rated $260,000 annual award. He will also receive cash compensation pursuant to the Company's non-employee director compensation program, as described in the “Non-Employee Director Compensation” section of Company's proxy statement filed with the Securities and Exchange Commission on April 6, 2026, as may be adjusted by the Board from time to time.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosures On June 25, 2026, the Company issued a press release announcing the appointment of Mr. Mazelsky to the Board. A copy of that press release is furnished herewith as Exhibit 99.1.

Filed exhibits (1)

EX-99.1 (by filename) podd-2026x6x25ex991.htm

EX-99.1 2 podd-2026x6x25ex991.htm EX-99.1 Document Exhibit 99.1 Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors ACTON, Mass. - June 25, 2026 - (BUSINESS WIRE) - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. “We are pleased to welcome Jay to Insulet’s Board of Directors,” said President and CEO Ashley McEvoy. “Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leadership position. We look forward to working with Jay and leveraging his insights to help advance our mission focused on transforming the lives of people with diabetes around the world.” “I’m honored to join Insulet’s Board at such an exciting time in the Company’s growth journey,” said Jay Mazelsky. “I…

Open exhibit ↗